Asia-Pacific Cell Culture Market

Asia-Pacific Cell Culture Market Size (2024 to 2029)

The size of the cell culture market in the Asia Pacific was worth USD 4.45 billion in 2023. The Asia-Pacific market is estimated to be growing at a CAGR of 12.12% from 2024 to 2029 and be worth USD 8.84 bn by 2029 from USD 4.99 bn in 2024.

Cell culture is defined as removing cells from an animal or plant and the subsequent cultivation of the cells in an artificial environment. The cells may be removed from the tissue directly or by enzymatic action and transferred elsewhere to proliferate. Primary culture is the stage of the culture that is initially extracted and isolated. They eventually reach a stage where they occupy the entire substrate, and at this stage, they are transferred into a new growth vessel with a fresh growth medium to enable continued growth. This process is called subculture, and the stage is called confluence. Culture conditions vary, but it generally consist of a substrate or medium, growth factors, hormones, gases such as carbon dioxide and oxygen, and a regulated physio-chemical environment with set factors such as pH, osmotic pressure, and temperature.

The major factors affecting the Asia-Pacific Cell Culture market include the growing demand for biopharmaceuticals and the rising prevalence of stem cell research. Biopharmaceuticals like vaccines and antibodies and the growing healthcare costs are predicted to stimulate the demand for cell culture items. In addition, the growing area of stem cell research shows great scope for developing the cell culture market. Heavy investments in stem cell research and organ transplantation are expected to drive the market in the coming years.

The market is impeded by the rising ethical concerns due to animal sources in cell cultures. Regulatory bodies worldwide are taking steps regarding the same and enforcing stringent standards for cell culture. The high cost of cell biology research is another restraint for the growth of the market.

This research report on the Asia-Pacific cell culture market has been segmented and sub-segmented into the following categories:

Asia-Pacific Cell Culture Market - By Product:

• Equipment
  • Bioreactors
  • Cell Culture Vessels
  • Cell Culture Storage Equipment
  • Cell Culture Supporting Equipment
• Consumables
  • Sera, Media & Reagents
  • Bioreactor Accessories

Asia-Pacific Cell Culture Market - By Application:

• Biopharmaceutical
  • Vaccine Production
  • Diagnostics
  • Recombinant Therapeutic Proteins
• Cancer Research
• Stem Cell Technologies
• Drug Screening and Development
• Tissue Engineering & Regenerative Medicine
• Other Applications

Asia-Pacific Cell Culture Market - By End-User:

• Pharmaceutical and Biotechnology Companies
• Research Institutes

Asia-Pacific Cell Culture Market - By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

The Asia Pacific region is expected to show the fastest growth during the forecast period. This could be due to higher healthcare costs, higher per capita income, and improved economic conditions in India and China. Thanks to advanced research on stem cell therapy, Japan also has significant room for growth. This trend is expected to benefit the entire Asia Pacific market in the future. Many clinical research organizations and biopharmaceutical companies target drug discovery and development in Asian countries such as China and India. The use of large regional genomic libraries, loose regulations on biologics development, and the development of healthcare infrastructure are key factors supporting local industries' growth.

KEY MARKET PLAYERS:

Some of the notable companies leading the APAC cell culture market profiled in the report are Thermo Fisher Scientific, GE Healthcare, Merck KGaA, Sartorius AG, Eppendorf AG, Lonza AG, Corning, Becton, Dickinson and Company, Promocell GmbH, and Hi-Media Laboratories.